RGD Reference Report - Association of Retinol-Binding Protein 4 with Arteriovenous Fistula Dysfunction in Hemodialysis Patients. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Association of Retinol-Binding Protein 4 with Arteriovenous Fistula Dysfunction in Hemodialysis Patients.

Authors: Wu, Yuanhao  Wang, Fan  Wang, Tingting  Zheng, Yin  You, Li  Xue, Jun 
Citation: Wu Y, etal., Blood Purif. 2021;50(6):906-913. doi: 10.1159/000513418. Epub 2021 Feb 8.
RGD ID: 329845868
Pubmed: PMID:33556944   (View Abstract at PubMed)
DOI: DOI:10.1159/000513418   (Journal Full-text)


BACKGROUND: Arteriovenous fistula (AVF) is the most common vascular access for patients undergoing hemodialysis (HD). Neointimal hyperplasia (NIH) might be a potential mechanism of AVF dysfunction. Retinol-binding protein 4 (RBP4) may play an important role in the pathogenesis of NIH. The aim of this study was to investigate whether AVF dysfunction is associated with serum concentrations of RBP4 in HD subjects.
METHODS: A cohort of 65 Chinese patients undergoing maintenance HD was recruited between November 2017 and June 2019. The serum concentrations of RBP4 of each patient were measured with the ELISA method. Multivariate logistic regression was used to analyze data on demographics, biochemical parameters, and serum RBP4 level to predict AVF dysfunction events. The cutoff for serum RBP4 level was derived from the highest score obtained on the Youden index. Survival data were analyzed with the Cox proportional hazards regression analysis and Kaplan-Meier method.
RESULTS: Higher serum RBP4 level was observed in patients with AVF dysfunction compared to those without AVF dysfunction events (174.3 vs. 168.4 mg/L, p = 0.001). The prevalence of AVF dysfunction events was greatly higher among the high RBP4 group (37.5 vs. 4.88%, p = 0.001). In univariate analysis, serum RBP4 level was statistically significantly associated with the risk of AVF dysfunction (OR = 1.015, 95% CI 1.002-1.030, p = 0.030). In multivariate analysis, each 1.0 mg/L increase in RBP4 level was associated with a 1.023-fold-increased risk of AVF dysfunction (95% CI for OR: 1.002-1.045; p = 0.032). The Kaplan-Meier survival analysis indicated that the incidence of AVF dysfunction events in the high RBP4 group was significantly higher than that in the low-RBP4 group (p = 0.0007). Multivariate Cox regressions demonstrated that RBP4 was an independent risk factor for AVF dysfunction events in HD patients (HR = 1.015, 95% CI 1.001-1.028, p = 0.033).
CONCLUSIONS: HD patients with higher serum RBP4 concentrations had a relevant higher incidence of arteriovenous dysfunction events. Serum RBP4 level was an independent risk factor for AVF dysfunction events in HD patients.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
RBP4HumanArteriovenous Fistula exacerbatesIEP protein:increased expression:blood serum (human)RGD 
Rbp4RatArteriovenous Fistula exacerbatesISORBP4 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
Rbp4MouseArteriovenous Fistula exacerbatesISORBP4 (Homo sapiens)protein:increased expression:blood serum (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Rbp4  (retinol binding protein 4)

Genes (Mus musculus)
Rbp4  (retinol binding protein 4, plasma)

Genes (Homo sapiens)
RBP4  (retinol binding protein 4)


Additional Information